Multiple studies have shown that cancer-specific alternative splicing (AS) alterations are associated with clinical outcome. In this study, we aimed to profile prognostic AS signatures for pancreatic ductal adenocarcinoma (PDAC). We integrated the percent-spliced-in (PSI) data of AS in 140 PDAC patients based on the Cancer Genome Atlas (TCGA) dataset. We identified overall survival (OS)-associated AS events using univariate Cox regression analysis. Then, prognostic AS signatures were constructed for OS and chemoresistance prediction using the least absolute shrinkage and selection operator (LASSO) method. We also analyzed splicing factors (SFs) regulatory networks by Pearson's correlation. We detected 677 OS-related AS events in 485 genes by profiling 10,354 AS events obtained from 140 PDAC patients. Gene functional enrichment analysis demonstrated the pathways enriched by survival-associated AS. The AS signatures constructed with significant survival-associated AS events revealed high performance in predicting PDAC survival and gemcitabine chemoresistance. The area under the receiver operator characteristic curve was 0.937 in training cohort and 0.748 in validation cohort at 2000 days of OS. Furthermore, we identified prognostic SFs (e.g., ESRP1 and HNRNPC) to build the AS regulatory network. We constructed AS signatures for OS and gemcitabine chemoresistance in PDAC patients, which may provide clues for further experiment-based mechanism study.
Get full access to this article
View all access options for this article.
References
1.
Abou FaycalC., GazzeriS., and EyminB. (2016). RNA splicing, cell signaling, and response to therapies. Curr Opin Oncol, 28, 58–64.
2.
ArafatH., LazarM., SalemK., ChipitsynaG., GongQ., PanT.C., et al. (2011). Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer. Surgery, 150, 306–315.
3.
CalabrettaS., BielliP., PassacantilliI., PilozziE., FendrichV., CapursoG., et al. (2016). Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene, 35, 2031–2039.
4.
CarriganP.E., BinghamJ.L., SrinvasanS., BrentnallT.A., and MillerL.J. (2011). Characterization of alternative spliceoforms and the RNA splicing machinery in pancreatic cancer. Pancreas, 40, 281–288.
5.
ChenL., YaoY., SunL., ZhouJ., MiaoM., LuoS., et al. (2017). Snail driving alternative splicing of CD44 by ESRP1 enhances invasion and migration in epithelial ovarian cancer. Cell Physiol Biochem, 43, 2489–2504.
6.
DavidC.J., and ManleyJ.L. (2010). Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev, 24, 2343–2364.
7.
GhignaC., ValaccaC., and BiamontiG. (2008). Alternative splicing and tumor progression. Curr Genomics, 9, 556–570.
8.
GoemanJ.J. (2010). L1 penalized estimation in the Cox proportional hazards model. Biom J, 52, 70–84.
9.
HeinhuisB., PlantingaT.S., SemangoG., KüstersB., NeteaM.G., DinarelloC.A., et al. (2016). Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. Carcinogenesis, 37, 197–205.
10.
HillisA.L., LauA.N., DevoeC.X., DaytonT.L., DanaiL.V., Di VizioD., et al. (2018). PKM2 is not required for pancreatic ductal adenocarcinoma. Cancer Metab, 6, 17.
11.
HongW., ZhangC.Z., LuS.X., ZhangM.F., LiuL.L., LuoR.Z., et al. (2019). A CCDC50 splice variant is modulated by SRSF3 and promotes hepatocellular carcinoma via the Ras signaling pathway. Hepatology, 69, 179–195.
12.
HoshidaY., VillanuevaA., KobayashiM., PeixJ., ChiangD.Y., CamargoA., et al. (2008). Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med, 359, 1995–2004.
13.
HosiosA.M., FiskeB.P., GuiD.Y., and Vander HeidenM.G. (2015). Lack of evidence for PKM2 protein kinase activity. Mol Cell, 59, 850–857.
14.
IsraelsenW.J., DaytonT.L., DavidsonS.M., FiskeB.P., HosiosA.M., BellingerG., et al. (2013). PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell, 155, 397–409.
15.
KahlesA., LehmannK.V., ToussaintN.C., HuserM., StarkS.G., SachsenbergT., et al. (2018). Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell, 34, 211.e6–224.e6.
16.
KarousouE., MisraS., GhatakS., DobraK., GotteM., VigettiD., et al. (2017). Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer. Matrix Biol, 59, 3–22.
17.
KashyapT., PramanikK.K., NathN., MishraP., SinghA.K., NaginiS., et al. (2018). Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3beta signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer. Oral Oncol, 86, 234–243.
18.
KlettH., FuellgrafH., Levit-ZerdounE., HussungS., KowarS., KustersS., et al. (2018). Identification and validation of a diagnostic and prognostic multi-gene biomarker panel for pancreatic ductal adenocarcinoma. Front Genet, 9, 108.
19.
KlingbeilP., MarhabaR., JungT., KirmseR., LudwigT., and ZollerM. (2009). CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol Cancer Res, 7, 168–179.
20.
KohC.M., BezziM., LowD.H., AngW.X., TeoS.X., GayF.P., et al. (2015). MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature, 523, 96–100.
21.
KozlovskiI., SiegfriedZ., Amar-SchwartzA., and KarniR. (2017). The role of RNA alternative splicing in regulating cancer metabolism. Hum Genet, 136, 1113–1127.
22.
LauA.N., IsraelsenW.J., RoperJ., SinnamonM.J., GeorgeonL., DaytonT.L., et al. (2017). PKM2 is not required for colon cancer initiated by APC loss. Cancer Metab, 5, 10.
23.
LiS., HuZ., ZhaoY., HuangS., and HeX. (2019). Transcriptome-wide analysis reveals the landscape of aberrant alternative splicing events in liver cancer. Hepatology, 69, 359–375.
24.
LiY., SunN., LuZ., SunS., HuangJ., ChenZ., et al. (2017). Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Lett, 393, 40–51.
25.
LiZ., ChenK., JiangP., ZhangX., LiX., and LiZ. (2014). CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients. Diagn Pathol, 9, 79.
26.
LiauS.S., and WhangE. (2008). HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res, 14, 1470–1477.
27.
LongJ.C., and CaceresJ.F. (2009). The SR protein family of splicing factors: master regulators of gene expression. Biochem J, 417, 15–27.
28.
MaoS., LiY., LuZ., CheY., SunS., HuangJ., et al. (2019). Survival-associated alternative splicing signatures in esophageal carcinoma. Carcinogenesis, 40, 121–130.
29.
MelchionnaR., IapiccaP., Di ModugnoF., TronoP., SperdutiI., FassanM., et al. (2016). The pattern of hMENA isoforms is regulated by TGF-beta1 in pancreatic cancer and may predict patient outcome. Oncoimmunology, 5, e1221556.
30.
MiyoshiS., TsugawaH., MatsuzakiJ., HirataK., MoriH., SayaH., et al. (2018). Inhibiting xCT improves 5-fluorouracil resistance of gastric cancer induced by CD44 variant 9 expression. Anticancer Res, 38, 6163–6170.
31.
OlteanS., and BatesD.O. (2014). Hallmarks of alternative splicing in cancer. Oncogene, 33, 5311–5318.
PivaF., GiuliettiM., BuriniA.B., and PrincipatoG. (2012). SpliceAid 2: a database of human splicing factors expression data and RNA target motifs. Hum Mutat, 33, 81–85.
34.
PradellaD., NaroC., SetteC., and GhignaC. (2017). EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression. Mol Cancer, 16, 8.
35.
QiaoG.L., SongL.N., DengZ.F., ChenY., and MaL.J. (2018). Prognostic value of CD44v6 expression in breast cancer: a meta-analysis. Onco Targets Ther, 11, 5451–5457.
36.
RajeshkumarN.V., YabuuchiS., PaiS.G., De OliveiraE., KamphorstJ.J., RabinowitzJ.D., et al. (2017). Treatment of pancreatic cancer patient-derived xenograft panel with metabolic inhibitors reveals efficacy of phenformin. Clin Cancer Res, 23, 5639–5647.
37.
SaitoY., KanaiY., SakamotoM., SaitoH., IshiiH., and HirohashiS. (2002). Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis. Proc Natl Acad Sci U S A, 99, 10060–10065.
38.
SaltonM., and MisteliT. (2016). Small molecule modulators of pre-mRNA splicing in cancer therapy. Trends Mol Med, 22, 28–37.
39.
SchaferS., MiaoK., BensonC.C., HeinigM., CookS.A., and HubnerN. (2015). Alternative splicing signatures in RNA-seq data: percent spliced in (PSI). Curr Protoc Hum Genet, 87, 11.6.1–11.16.14.
40.
ShiloA., Ben HurV., DenichenkoP., SteinI., PikarskyE., RauchJ., et al. (2014). Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development. RNA, 20, 505–515.
41.
StathisA., and MooreM.J. (2010). Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol, 7, 163–172.
42.
SuoC., HrydziuszkoO., LeeD., PramanaS., SaputraD., JoshiH., et al. (2015). Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival. Bioinformatics, 31, 2607–2613.
43.
TangS.C., and ChenY.C. (2014). Novel therapeutic targets for pancreatic cancer. World J Gastroenterol, 20, 10825–10844.
44.
WagnerG.P., KinK., and LynchV.J. (2013). A model based criterion for gene expression calls using RNA-seq data. Theory Biosci, 132, 159–164.
45.
WahlM.C., WillC.L., and LuhrmannR. (2009). The spliceosome: design principles of a dynamic RNP machine. Cell, 136, 701–718.
46.
WangE.T., SandbergR., LuoS., KhrebtukovaI., ZhangL., MayrC., et al. (2008). Alternative isoform regulation in human tissue transcriptomes. Nature, 456, 470–476.
47.
WangJ., DumartinL., MafficiniA., UlugP., SangaralingamA., AlamiryN.A., et al. (2017). Splice variants as novel targets in pancreatic ductal adenocarcinoma. Sci Rep, 7, 2980.
48.
WojtuszkiewiczA., AssarafY.G., MaasM.J., KaspersG.J., JansenG., and CloosJ. (2015). Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance. Expert Opin Drug Metab Toxicol, 11, 673–689.
49.
XiongY., DengY., WangK., ZhouH., ZhengX., SiL., et al. (2018). Profiles of alternative splicing in colorectal cancer and their clinical significance: a study based on large-scale sequencing data. EBioMedicine, 36, 183–195.
50.
YangC., WuQ., HuangK., WangX., YuT., LiaoX., et al. (2019). Genome-wide profiling reveals the landscape of prognostic alternative splicing signatures in pancreatic ductal adenocarcinoma. Front Oncol, 9, 511.
51.
ZhangD., DuanY., CunJ., and YangQ. (2019). Identification of prognostic alternative splicing signature in breast carcinoma. Front Genet, 10, 278.
52.
ZhouZ., ChengY., JiangY., LiuS., ZhangM., LiuJ., et al. (2018). Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis. Int J Biol Sci, 14, 124–136.
53.
ZhuJ., ChenZ., and YongL. (2018). Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer. Gynecol Oncol, 148, 368–374.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
